Trial Profile
Efficacy of ranibizumab on vascularized pigment epithelial detachment in patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 28 Aug 2017 New trial record